SEC Company Response from X4 Pharmaceuticals, Inc (XFOR) (CIK 0001501697) (XFOR) — Feb 12, 2019
X4 Pharmaceuticals, Inc (XFOR) (CIK 0001501697)
Date: Feb. 12, 2019 · CIK: 0001501697 · Accession: 0001193125-19-035896
AI Filing Summary & Sentiment
File numbers found in text: 333-229377
Show Raw Text
CORRESP 1 filename1.htm CORRESP Arsanis, Inc. 950 Winter Street, Suite 4500 Waltham, MA 02451 February 12, 2019 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Arsanis, Inc. Registration Statement on Form S-3 File No. 333-229377 Request for Acceleration Ladies and Gentlemen: Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Arsanis, Inc. (the “Registrant”) hereby requests acceleration of the effective date of its Registration Statement on Form S-3 (File No. 333-229377), as amended (the “Registration Statement”), so that it may become effective at 4:00 p.m. Eastern time on February 14, 2019, or as soon thereafter as practicable. [Remainder of Page Intentionally Left Blank] Very truly yours, ARSANIS, INC. By: /s/ Michael P. Gray Name: Michael P. Gray Title: President and Chief Executive Officer, Chief Financial Officer Signature Page to Acceleration Request